tbuckley/cabot-search huggingface dataset:
Abstract 11333: Identifying Patients at Low Risk for Ventricular Tachycardia After Cardiac Resynchronisation
Authors: Martin Grett, Hans-Joachim Trappe
Journal: Circulation (2014)

Introduction:  Ruling out scar as a substrate and ischemia as a trigger of ventricular tachyarrhythmia could define patients (pts) at low risk for adequate ICD-therapies despite poor left ventricular ejection fraction (LVEF). The modified Selvester-ECG-score (MSES) correlates with the LV scar burden. Every 1 point raise counts for 3% additional scar. In a retrospective analysis of SCD-HeFT it has shown a value in describing pts at high vs low risk for ICD-therapy. Its value in pts with non-ischemic cardiomyopathy and indication for CRT has not yet been described.   Hypothesis: A low MSES, non-ischemic cardiomyopathy and CRT can define pts at low risk for adequate ICD-therapies   Methods:  We studied 54 pts who underwent primary prophylactic CRT-D implantation at our department, had non-ischemic cardiomyopathy and complete follow up of device interrogation for 1 year. For 44 of these pts a complete follow up of 2 years was obtainable. Pts with upgrade from existing devices were not studied.   Results:  Mean LVEF was 21,1% (range 10,0%-30,0%), median MSES was 3 (0-11). 9/54 pts suffered adequate ICD-therapy in the first year, 12/44 over the 2 year period. The LVEF of pts with and without ICD-therapy did not differ significantly. Median MSES was 6 in the therapy group and 3 in pts without therapy. No pt with an MSES of 3 or less suffered an ICD-therapy. The risk for ICD-therapy in pts with an MSES of 4 or more vs. 3 or less showed a significant difference: relative risk was for the first year 20,4 (95% CI 1,3-334,0, p=0,03), for the 2 year period 21,0 (95% CI 1.3-334.0, p=0.03). Calculating the relative risk using a LVEF cut-off of 20% lead to no significant results in both periods. LVEF and MSES showed no correlation (spearman’s rho -0,12, two-tailed p = 0,37).   Conclusions:  We could clearly demonstrate that applying the modified Selvester-ECG-score to pts with non-ischemic cardiomyopathy and indication for CRT is a promising way to identify pts at low risk for ICD-therapy. The score is superior to LVEF and does not correlate with it. In particular pts with a score ≤ 3 have a very low risk for adequate ICD-therapy. Management of pts with indication for CRT could be improved by use of this parameter, particularly with regard to the question if a CRT-P is an alternative in more pts.
EOSINOPHILIA IN MALIGNANT TUMORS: ITS SIGNIFICANCE
Authors: N H ISAACSON, P RAPOPORT
Journal: Annals of Internal Medicine (1946)

ExcerptEhrlich,20 in 1880, was the first to stain and definitely describe the eosinophile, though previous investigators29, 30 seem to have recognized the coarse granules in the unstained cells. Ehrlich believed that eosinophiles originated and matured in the bone marrow and were delivered into the circulating blood as a definite cell type. This concept is still considered to be correct.Most hematologists21, 22, 23, 26today agree that 6 per cent of the total white cell count is the upper limit of normal for eosinophilic leukocytes. Kirk24recently made an extensive review of the literature on eosinophilia and reported an eosinophile...
Abstract 8423: Prevalence and Outcomes of Intermediate Saphenous Vein Graft Lesions: Findings from the Stenting of Saphenous Vein Grafts Randomized-Controlled Trial
Authors: Abdul-rahman R Abdel-karim, Monica da Silva, Christopher Lichtenwalter, James A de Lemos, Owen Obel, Tayo Addo, Michele Roesle, Donald Haagen, Bavana V Rangan, Lorenza Makke, Omar M Jeroudi, Deepa Raghunathan, Bilal Saeed, Joseph K Bissett, Rajesh Sachdeva, Vassilios V Voudris, Panagiotis Karyofillis, Biswajit Kar, James Rossen, Panayotis Fasseas, Peter Berger, Subhash Banerjee, Emmanouil S Brilakis
Journal: Circulation (2011)

Background: We sought to examine the prevalence and progression rate of intermediate SVG lesions in the Stenting Of Saphenous vein grafts (SOS) trial. Methods: The baseline and follow-up angiograms of the 80 patients participating in the SOS trial were analyzed to determine the prevalence of intermediate (30-60% angiographic diameter stenosis) SVG lesions and their progression rate. Results: At least one intermediate SVG lesion was present in 31 of 143 (22%) SVGs in 27 of 80 (34%) patients. Patients with intermediate SVG lesions were older and more likely to present with myocardial infarction. Most intermediate lesions were present in the vein grafts the required stents (20 grafts in 19 patients). During a median follow-up of 35 months, angiographic follow-up was available for 28 grafts in 25 patients. Progression (defined as percent diameter stenosis ≥70% but &lt;100% at follow-up angiography) was seen in 11 of 28 SVGs (39%) in 11 of 25 patients (44%). The rate of progression of the intermediate lesion at 12, 24 and 36 months was 28% and 47% and 84%, respectively (Figure). Seven of 11 patients (64%) whose intermediate SVG lesion progressed presented with an acute coronary syndrome, and 8 (73%) underwent a percutaneous coronary intervention. Four of the 28 grafts with intermediate lesions at baseline were occluded at follow-up; all of those SVGs had received a stent as part of the SOS trial. Conclusions: Among patients undergoing SVG lesion stenting, intermediate SVG lesions are common, have high rates of progression, and frequently present as an acute coronary syndrome.
Adolescents and health.
Authors: Trevor Jackson
Journal: BMJ (2001)

In many ways, the internet seems made for teenagers. It allows them to shop, chat to their friends, catch up on the latest pop, sport, and fashion gossip, research their school or college essays, go job hunting, and indulge any slightly dodgy fringe interests without having to leave their bedroom. Any curfew obsessed home secretary must be delighted. A wealth of information abounds about …
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors
Authors: Amrita Krishnan, Smita Bhatia, Marilyn L. Slovak, Daniel A. Arber, Joyce C. Niland, Auayporn Nademanee, Henry Fung, Ravi Bhatia, Ashwin Kashyap, Arturo Molina, Margaret R. O'Donnell, Pablo A. Parker, Irena Sniecinski, David S. Snyder, Ricardo Spielberger, Anthony Stein, Stephen J. Forman
Journal: Blood (2000)
Early Triple Therapy vs Mono or Dual Therapy for Children With Perinatal HIV Infection
Authors: Elena Chiappini, Luisa Galli, Clara Gabiano, Pier-Angelo Tovo, Maurizio de Martino
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Differential global effects of selective estrogen receptor modulators on estrogen receptor binding and transcriptional regulation
Authors: Yew Kok Lee, Vinsensius B. Vega, Say Li Kong, Premila Hirubalan, Gary Siang Lin Loh, Haixia Li, Jun Tao Li, Radha Krishna Murthy Karuturi, Kartiki Desai, Jane Sohn Thomsen, Edison T.Liu
Journal: Clinical Cancer Research (2007)

AACR Centennial Conference: Translational Cancer Medicine-- Nov 4-8, 2007; Singapore

C18 

Selective estrogen receptor modulators (SERMs) are used clinically to treat breast cancer as they inhibit estrogen both in promoting cell proliferation and expressing ER-mediated gene expression. However, the complexity of estrogen receptor(ER) biology hinders an effective drug design. Our lab is interested in examining the global ER binding sites and the corresponding gene expression profiles upon treatment of ER by different SERMs.    Chromatin Immunoprecipitation assays (ChIP) were performed on MCF-7 breast tumor cells in the presence or absence of E2/SERMs or a combination of E2+SERMs. Subsequently, the ChIP samples were applied to Nimblegen tiling arrays, specially customized for ER binding sites, to investigate the different binding profiles. The sources of the probed regions came from ChIP-Clone experiments, ERE motif-finding program and published literature data. This allows for comprehensive survey more than 40,000 highly-putative ER binding sites at once. The array was covered with about 385,000 isothermal probes and each binding region was tiled with at least 6 probes. Nimblegen data obtained with presence or absence of E2 showed high correlations between replicates as well as high consistencies in detection of reported true ER binding sites.    Affymetrix experiments have been performed with different E2/SERMs treatments across varying time points in MCF-7 cells. The comprehensive expression data will be correlated with the binding profiles to infer direct target genes and functional binding sites.    Together, the information from binding sites and gene expression profiles upon drug treatments will help to decipher the mechanism of Estrogen Receptor gene regulation over time and over several pharmacologic interventions: E2 and SERMS.
Hypertension and Smoking Are Associated With Reduced Regional Left Ventricular Function in Asymptomatic Individuals
Authors: Boaz D. Rosen, Mohammed F. Saad, Steven Shea, Khurram Nasir, Thor Edvardsen, Gregory Burke, Michael Jerosch-Herold, Donna K. Arnett, Shenghan Lai, David A. Bluemke, João A.C. Lima
Journal: Journal of the American College of Cardiology (2006)
More Stringent Rules on Accutane
Authors: Brian Vastag
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE ROLE OF THORACOTOMY IN THE DIFFERENTIAL DIAGNOSIS OF PLEURAL EFFUSION
Authors: James M. Schless, Harold N. Harrison, James A. Wier
Journal: Annals of Internal Medicine (1959)

Article1 January 1959THE ROLE OF THORACOTOMY IN THE DIFFERENTIAL DIAGNOSIS OF PLEURAL EFFUSIONJAMES M. SCHLESS, M.D., HAROLD N. HARRISON, JAMES A. WIERJAMES M. SCHLESS, M.D.Search for more papers by this author, HAROLD N. HARRISONSearch for more papers by this author, JAMES A. WIERSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-50-1-11 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONIt has long been axiomatic that primary pleural effusion in tuberculin-positive individuals must be considered to be tuberculous until proved otherwise. The basis for this axiom arose in the pre-chemotherapy era when an appallingly high breakdown rate with significant tuberculous manifestations was noted in patients with pleural effusions followed for over five years.Roper and Waring, 1 for instance, reported an over-all five-year breakdown rate of 65.2% in 141 patients treated in Army hospitals in the years 1944 and 1945. The breakdown rate was 90.9% in those patients in their series treated with less than six months of bed-rest,...Bibliography1. RoperWaring WHJJ: Primary serofibrinous pleural effusions in military personnel, Am. Rev. Tuberc. 71: 616, 1955. MedlineGoogle Scholar2. Compton MA: Personal communication. Google Scholar3. BrecklerHenslerHillHoffmanHukell IANMHEMCPB: Biopsy technics in the diagnosis of intrathoracic disease, Ann. Int. Med. 46: 706, 1957. LinkGoogle Scholar4. DonohoeKatzMatthews RFSMJ: Aspiration biopsy of the parietal pleura, Am. J. Med. 22: 883, 1957. CrossrefMedlineGoogle Scholar5. SteadEichenholzStauss WWAHK: Operative and pathologic findings in twenty-four patients with syndrome of idiopathic pleurisy with effusion, presumably tuberculous, Am. Rev. Tuberc. 71: 473 (Apr.) 1955. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication December 23, 1957.From the Pulmonary Disease Service and the Department of Pathology, Fitzsimons Army Hospital, Denver, Colorado.Presented in condensed form at the Regional Meeting of The American College of Physicians, Colorado Springs, Colorado, January 17, 1958.Requests for reprints should be addressed to Chief, Pulmonary Disease Service, Fitzsimons Army Hospital, Denver 8, Colorado. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe treatment of tuberculous pericarditisTHE RELIABILITY OF TISSUE DIAGNOSIS OF PLEURISY: A PRELIMINARY REPORT*JOEL H. RICHERT, JAMES A. WIER, JOHN M. SALYER, JAMES C. BEYER 1 January 1959Volume 50, Issue 1Page: 11-33KeywordsPleural effusionPulmonary diseasesThoracotomyTuberculosis ePublished: 1 December 2008 Issue Published: 1 January 1959 PDF downloadLoading ...
CD4+ Count–Guided Interruption of Antiretroviral Treatment
Authors: Wafaa El-Sadr, Jens D Lundgren, James Neaton, Fred Gordin, DJ Abrams, Roberto Arduino, Abdel Babiker, William Burman, Nathan Clumeck, Calvin Cohen, David V. Cohn, David Cooper, Janet Darbyshire, Sean Emery, Gerd Fätkenheuer, Brian Gazzard, Birgit Grund, Jennifer Hoy, Karin Klingman, Marcello Losso, Norman Markowitz, J. Neuhaus, Andrew N. Phillips, C. Rappoport
Journal: New England Journal of Medicine (2006)

Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV).
227. Anatomical and Behavioral Effects of AAV2-Mediated Delivery of Neurturin to the Rat Striatum Prior to 6-Hydroxydopamine Induced Nigrostriatal Degeneration
Authors: Christopher D. Herzog, Mehdi Gasmi, Justine J. Cunningham, Eugene P. Brandon, Anthony Ramirez, Alistair Wilson, Eva K. Hofer, Jennifer Hwang, Leo Manlapaz, Jeffrey H. Kordower, Jeffrey M. Ostrove, Raymond T. Bartus
Journal: Molecular Therapy (2004)

The cardinal symptoms of Parkinson's disease (PD) are due to striatal dopamine insufficiency secondary to degeneration of dopaminergic neurons in the substantia nigra (SN) pars compacta. Several reports indicate that delivery of glial cell line-derived neurotrophic factor (GDNF), and more recently neurturin (NTN), to the nigrostriatal system has neuroprotective and restorative effects in rodent and non-human primate models of PD. Viral vector mediated gene transfer represents a potentially safe and effective method of delivering neurotrophic factors to degenerating neurons. Accordingly, we are developing an adeno-associated virus type 2 (AAV2) vector encoding neurturin (CERE-120) for the treatment of PD. The present experiments examined both the anatomical and behavioral effects of CERE-120 delivery to the striatum in a rodent 6-hydroxydopamine (6-OHDA) model of PD. The AAV2 vector was selected to deliver NTN cDNA to the striatum based upon its affinity for neurons and its capacity to promote efficient and stable transgene expression in these cells. To promote efficient secretion of mature NTN from transduced cells, the natural prepro domain of the human NTN cDNA was replaced with that of the human β-nerve growth factor (NGF) as described in a separate abstract at this meeting (Ramirez et al). An initial experiment was conducted to assess the short-term anatomical effects of CERE-120 when delivered to the striatum 2 weeks prior to 6-OHDA. Twenty-six rats received unilateral intrastriatal injections of CERE-120, AAV2-GDNF (both 1 × 1012 vector genomes/mL; 4 × 109 total vector genomes per animal; n = 8), or formulation buffer (negative control; n = 10) to the striatum in two injections of 2 μL each. Two weeks following vector administration, all animals received a single dose of 20 μg of 6-OHDA in a volume of 5 μL directly into the striatum on the side ipsilateral to the vector or control injections. Animals were sacrificed 2 weeks later. A robust immunohistochemical signal for GDNF or NTN was observed in the striatum and SN of all vector-injected animals. A similar and significant sparing of tyrosine hydroxylase (TH) positive nigral neurons was also observed in both CERE-120 and AAV2-GDNF treated animals (62–68% of the intact side). A second, longer-term study employing an identical experimental design is currently in progress to further characterize the anatomical as well as the behavioral effects of CERE-120 administration in this 6-OHDA model of nigrostriatal degeneration. Behavioral and histological data will be presented. These findings will collectively provide further information about the potential utility of CERE-120 for therapeutic intervention in Parkinson's disease.
Intraoperative Fluorescence Imaging for Sentinel Lymph Node Detection
Authors: Ingo Stoffels, Joachim Dissemond, Thorsten Pöppel, Dirk Schadendorf, Joachim Klode
Journal: JAMA Surgery (2015)

The metastatic status of regional lymph nodes is the most relevant prognostic factor in breast cancer, melanoma, and other solid organ tumors with a lymphatic spread. The current gold standard for detection and targeted excision of the sentinel lymph node is preoperative lymphoscintigraphy with technetium Tc 99m. Because of the worldwide shortage of technetium Tc 99m, physicians are looking for nonradioactive dyes for sentinel lymph node labeling. Based on several retrospective studies, the fluorescent dye indocyanine green is considered a possible alternative to technetium Tc 99m.To analyze the feasibility and clinical benefit of intraoperative near infrared fluorescence sentinel lymph node excision (SLNE) compared with standard technetium Tc 99m-guided SLNE using malignant melanoma in which SLNE is firmly established.Analysis of a prospective clinical trial at the Skin Cancer Center, University Hospital Essen. Eighty patients with malignant melanoma on the trunk or extremities (upper and lower) who were scheduled to undergo SLNE were included in this study from January 1, 2013, to June 27, 2014.Concordance of preoperative and intraoperative sentinel lymph node detection rates.During the study period, 80 patients were operated on with an additional intraoperative application of a near infrared fluorescent dye. In these 80 surgical procedures, 147 SLNs were excised. Detection of a technetium Tc 99m-marked SLN before surgery was possible in all cases. Intraoperative visualization of the SLN by indocyanine green before skin incision was successful in only 17 of 80 patients (21%). The number of SLNs identified using the near infrared fluorescence technique in the operative site after skin incision and initial tissue preparation was 141 of 147 (96%).Among patients in whom the lymph node basin cannot be predicted correctly (eg, in cutaneous melanoma on the trunk), the use of indocyanine green for SLN detection is severely limited compared with SLNE using standard technique guided by technetium Tc 99m. Therefore, SLNE with the use of radiocolloid, followed if possible by single-photon emission computed tomography, remains the gold standard.German Clinical Trials Register identifier DRKS00004619.
Abstract P326: Progression of ECG Abnormalities through Young Adulthood and Early Cardiovascular Events: Coronary Artery Risk Development in Young Adults (CARDIA) Study
Authors: Donald M Lloyd-Jones, Hongyan Ning, Kiang Liu, Cora E Lewis, Pamela J Schreiner, Stephen X Sidney, Mark D Huffman, Elsayed Z Soliman
Journal: Circulation (2014)

Background: In older adults, ECG abnormalities are associated with significant independent risk for cardiovascular disease (CVD). However, the progression of ECG abnormalities from young adulthood to middle age and the implications of ECG progression as a risk marker for premature CVD events are poorly described. Methods: CARDIA is a NHLBI-funded longitudinal cohort study of black and white men and women aged 18-30 years at baseline (Year 0) in 1985. We included all CARDIA participants (ppts) who had resting 12-lead ECGs performed at the Year 0, 7 and 20 examinations. We classified ppts into one of 3 strata based on ECG findings (Minnesota code normal, minor, major) across time: 1) Always Normal at all 3 exams; 2) baseline minor or major abnormalities with Regression/No Progression over time; or 3) Progression of ECG from normal to minor or major, or minor to major, over time. We used Cox proportional hazards models to assess risk for adjudicated incident CVD events (MI, stroke, CHF) by ECG stratum during 25 years’ follow up. Results: There were 2193 ppts: 63.0% were Always Normal, 14.2% had Regression/No Progression, and 22.8% showed Progression. Those with Progression were more likely to be black and to smoke and had a slightly higher BMI. Baseline ECG abnormalities (major or minor) were not associated with increased risk for CVD. Among the Always Normal, Regression/No Progression and Progression groups, CVD incidence rates (per 1000 p-y) were 0.73, 0.13 and 1.85, respectively. In unadjusted models, those with Progression were 2.5 times more likely than those with Always Normal ECGs to develop incident CVD; these findings were attenuated by adjustment for demographics and clinical risk factors (Table). Those with Regression/No Progression were at lower risk. Conclusions: Progression of ECG findings from normal to abnormal or from minor to major abnormalities during young adulthood may be a useful marker of risk, identifying those destined to develop premature CVD events.